. Author manuscript; available in PMC: 2013 Oct 1.

Published in final edited form as: Pediatr Blood Cancer. 2012 Feb 7;59(4):753–755. doi: 10.1002/pbc.23391

Table I.

Summary of Arsenic Trioxide in Vitro Activity

Cell Line	Histology	Relative IC₅₀ (μM)	R²	Panel rIC₅₀/ Line rIC₅₀	Ymin (%)
RD	Rhabdomyosarcoma	0.9	0.95	0.95	0.1
Rh41	Rhabdomyosarcoma	0.5	0.99	1.66	0.0
Rh18	Rhabdomyosarcoma	1.6	0.97	0.56	2.0
Rh30	Rhabdomyosarcoma	0.8	0.97	1.08	0.3
BT-12	Rhabdoid	0.8	0.99	1.09	0.1
CHLA-266	Rhabdoid	0.4	0.91	2.06	0.2
TC-71	Ewing sarcoma	0.6	0.99	1.40	0.0
CHLA-9	Ewing sarcoma	1.2	0.98	0.73	0.1
CHLA-10	Ewing sarcoma	1.0	0.98	0.90	0.1
CHLA-258	Ewing sarcoma	0.5	0.88	1.77	0.0
SJ-GBM2	Glioblastoma	0.9	0.95	0.96	1.6
NB-1643	Neuroblastoma	1.9	0.95	0.47	1.1
NB-EBc1	Neuroblastoma	1.5	0.99	0.57	1.1
CHLA-90	Neuroblastoma	3.7	0.97	0.24	3.5
CHLA-136	Neuroblastoma	4.7	0.92	0.18	3.3
NALM-6	ALL	0.9	0.98	1.00	0.0
COG-LL-317	ALL	0.2	0.96	4.68	0.0
RS4-11	ALL	0.9	0.99	1.00	0.1
MOLT-4	ALL	1.3	0.91	0.69	2.1
CCRF-CEM (1)	ALL	0.7	0.99	1.25	0.0
CCRF-CEM (2)	ALL	0.6	0.96	1.48	0.0
Kasumi-1	AML	0.8	0.99	1.05	0.4
Karpas-299	ALCL	0.4	0.98	1.95	0.0
Ramos-RA1	NHL	0.9	0.95	0.95	0.0
Median Summary Data		0.9	0.97	1.00	0.10
Minimum		0.2	0.88	0.18	0.00
Maximum		4.7	0.99	4.68	3.49